CFTY720DDE18, NIS334) was a prospective, multi-center non-interventional study which was conducted in neurological and other medical practices or hospitals, qualified to routinely assess electrocardiogram (ECG) findings. Data were collected through interviews, clinical evaluations (notably ECGs), and laboratory tests. Medical history, vital signs, and a 12-lead ECG were assessed before fingolimod administration. After the first dose, a 6 h ECG was performed and vital signs (blood pressure and HR) were measured hourly. The occurrence of bradycardia (HR B45 beats per minute [BPM] ), AV blocks (2nd degree Mobitz type I or higher), and corrected QT interval (QTc) intervals was also documented.
Results: More than 95% of physicians adhered to the cardiac monitoring recommendations. The observation of 217 patients in 42 study centers showed that while 35.9% of the patients had any cardiac risk profile, none of them experienced a bradycardia during the 6 h post-dose observation. Overall, only 1.8% of all patients displayed bradycardia (HR B45 BPM) during 6 h after treatment initiation. Moreover, in this cohort, none of the patients showed a new or persistent onset AV block (2nd degree Mobitz type I or higher) or QTc C500 ms.
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INTRODUCTION
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system leading to inflammation and destruction of myelin and axons [1] . A worldwide average incidence of 2.5 per 100,000 people with a variance of 1. signs, and a pre-dose 12-lead ECG were assessed before fingolimod administration. After the first dose, a 6 h continuous ECG was performed and vital signs (blood pressure and heart rate [HR]) were measured and documented hourly. The occurrence of bradycardia (HR B45 BPM), AV blocks (2nd degree Mobitz type I or higher), and corrected QT interval (QTc) interval was also documented.
Statistical Analysis
Outcomes of this study were the incidence with 95% confidence intervals of the aforementioned cardiac parameters, occurring during or at the end of the 6 h observation period after therapy start with fingolimod. The analysis was performed using the SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA). The number of participating centers and enrolled patients (42 centers and 217 patients) was lower than expected (2000 patients), resulting in a relatively small sample size. Therefore, only descriptive statistics are presented in this paper.
RESULTS
From February 2012 to April 2015, 217 patients were enrolled at 42 study centers (5.2 ± 5.5 patients/center). The mean age of the 58 males (26.7%) and 159 females (73.3%) included was 39.8 ± 9.8 years (see Table 1 ). Data on MS history are also summarized in Course of blood pressure and HR course at baseline and during the 6 h observation period are summarized in Fig. 1a and b. The detailed HR course is also represented in Table 2 . During the observation period, blood pressure remained relatively stable; only a slight decrease in the mean blood pressure (systolic and diastolic) was observed (Fig. 1a) . The lowest mean systolic blood pressure (120.4 ± 13.9 mmHg) was observed, 2 h after treatment start and 5 h after treatment start, the lowest mean diastolic blood pressure (76.7 ± 10.0 mmHg). Patients receiving the first dose of fingolimod experienced, on Beta blockers 2 (0.9)
Other agents that may lower the heart rate 2 (0.9) BPM during or at the end of the observation period, was reported for four and three patients (1.8% and 1.4%, respectively). ''Other'' cardiac events were documented for nine and four patients (4.3% and 1.8%, respectively) during or at the end of the observation period. These events mostly referred to a low HR which did, however, not meet the criteria of a bradycardia (45-60 BPM) or AV block other than 2nd or 3rd degree (i.e. AV-block 1st degree). None of these Fig. 1 Evolution of vital signs and cardiac events during and after the 6 h monitoring post-treatment initiation. a Systolic and diastolic blood pressure course at baseline and during the 6 h observation period (in mmHg, each value represents the mean ± SD, n = 215). b Heart rate course at baseline and during the 6 h observation period (in BPM, each value represents the mean ± SD, n = 215). BPM beats per minute, SD standard deviation Table 2 Heart rate course (in BPM) at baseline and during the 6 h observation period (n = 215) 
DISCUSSION
Here, we analyze the cardiac side effects after the first dose of fingolimod in everyday practice and confirm the well-known favorable cardiac safety profile of this compound in a real-world setting. None of the few cardiac events in this study required medical attention. The positive cardiac safety profile also extended to blood pressure analyses with only mild changes in systolic and diastolic blood pressure and even to the 35.9% of patients in the study with any cardiac risk factor (mainly tobacco use, overweight, hypertension, or patients taking cardiovascular co-medications, see Table 1 ). The Table 3 Patients with cardiac events during and/or at the end of the 6 h observation period
During the observation period
At the end of the observation period N 5 217 n (%) 
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